Fact.MR forecasts the global carglumic acid market to grow from US$ 152.5 million in 2023 to US$ 314.4 million in 2033. This represents a CAGR of over 7.5% from 2023 to 2033.
Carglumic acid, a synthetic structural analog of N-acetylglutamate (NAG), is primarily used to treat hyperammonemia due to N-acetylglutamate synthase (NAGS) deficiency. This rare genetic disorder leads to an accumulation...
Arabic
Français
Español
Português
Deutsch
Türkçe
Dutch
Italiano
Russian
Romaian